A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer

Trial Profile

A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2011

At a glance

  • Drugs Falimarev (Primary) ; Inalimarev (Primary)
  • Indications Advanced breast cancer; Breast cancer; Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Nov 2011 New trial record
    • 08 Nov 2011 Results published in the Clinical Cancer Research journal, according to a Bavarian Nordic media release. Results were also reported in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top